Iol Chem And Pharma Ltd

IOLCP NSE Healthcare Pharmaceuticals
₹194.31
-8.10%
Delayed · cached 15 min

Fair value analysis

IOLCP
Iol Chem And Pharma Ltd
HealthcarePharmaceuticals
₹211.43
Close used for this calculation
₹125.79Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
37/100
Profitability6/25
Returns4/25
Balance Sheet21/25
Efficiency6/25
Growth0/25
Average
Quality radar
37Prof.6/25Ret.4/25Eff.6/25B.Sht21/25Growth0/25

Consensus fair value

₹125.79
Above FV
▼ -40.5% against the close used
Model range ₹29.87 – ₹167.43
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear₹29.87Fair value₹125.79Bull₹167.43
FairClose
52-week traded range
52W low ₹68.2152W high ₹213.04

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

Iol Chem And Pharma Ltd closed at ₹211.43, 68.1% above the consensus fair value of ₹125.79 drawn from 7 valuation models.

Financial DNA score 37/100 — Average. P/E of 32.3x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation
₹29.87
-85.9%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=8%, r=10%, tg=3%, n=10yr
Graham Number
₹95.04
-55.0%
√(22.5 × EPS × BVPS)
EPS=4.69, BVPS=85.6 · outside Graham range (P/E 32.3, P/B 2.5) — asset-light, treat as a rough floor
P/E Fair Value
₹167.43
-20.8%
EPS × 35.7x (sector P/E)
EPS=4.69, Sector P/E=35.7x
EV/EBITDA
₹124.73
-41.0%
(EBITDA × 10x − Net Debt) ÷ Shares
EBITDA=3.5B
Book Value (P/B)
₹66.16
-68.7%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=85.6, ROE=8.4%, g=3%, r=10%
Reverse DCF
₹211.43
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 18.1% | Historical: 0%
Margin of Safety
₹73.09
-65.4%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=97.45, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Educational data only. Not a recommendation to buy, sell or hold any security.